Episode Details

Hims & Hers Health just suffered a brutal 18% selloff after third-quarter margins collapsed from 74% to 57% and sequential subscriber numbers dropped. Despite revenue jumping 49%, Wall Street hit the panic button over slashed EBITDA guidance, soft forecasts, and insider stock sales. In this episode of Implied, we break down what’s really driving the margin squeeze, how international expansion and new clinical verticals fit into management's long-term dominance bet, and whether this steep drop offers a rare, high-upside buying opportunity.